Sativex

"In 1998, GW Pharmaceuticals was established in the United Kingdom to develop a cannabis-based medicine (CBM). The British government gave its support to the project. The two main problems were the production of a standardized formulation of cannabis and the development of appropriate method(s) of drug delivery...
While the extracts of cannabis were being developed, the problem of how to deliver them was addressed...
The possibility of sublingual administration (under the tongues) was considered. A description of the administration by this route was described as early as 1897 (Marshall 1897). The extract would be sprayed onto the lining of the mouth and absorbed directly into the bloodstream. This gave the possibility of a faster effect than seen by other routes, except inhalation into the lungs (smoking) or intravenous. Preclinical trials carried out on healthy human volunteers showed the absorption occurred within fifteen to twenty minutes...
CBD alone did not seem to be nearly as beneficial. It was therefore decided to focus the next cohort of studies on the 1:1 mixture of THC and CBD. This mixture of cannabinoids (with ethanol and propylene glycol 1:1,to aid stray delivery and peppermint flavouring) came to be known as Sativex (sativa extract). In producing Sativex, ethanol (alcohol) is not used to extract cannabinoids from the plant material, unlike with previous tinctures."

-pp. 337- 339, "Sativex" by Dr. William Notcutt in The Pot Book: A Complete Guide to Cannabis (2010)

Sativex
Sativex
ShareThis